Angiocrine Bioscience
Blood & Organ Banks · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11575 Sorrento Valley Rd Ste 217, San Di...Phone Number
(858) 345-1396Website
www.angiocrinebioscience.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
2
8
6
2
About Angiocrine Bioscience
Angiocrine Bioscience specializes in cellular therapies aimed at restoring, regenerating, and repairing tissues and organs. Their innovative E-CEL Therapies are designed to positively impact patients' lives through their reparative capabilities. The company is focused on transforming medicine by leveraging the power of cellular therapies. Their intended clients include patients in need of advanced therapeutic solutions.Explore more
Angiocrine Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Angiocrine Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Angiocrine Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Angiocrine Bioscience is spiking on competitors!
Funding: Get notified immidiatlly once Angiocrine Bioscience has new funding data
Click to see if Angiocrine Bioscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Angiocrine Bioscience has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Angiocrine Bioscience launches new products
Congratulate Masked Content for being promoted to Masked Content at Angiocrine Bioscience
Earning: See what the market has to say on Angiocrine Bioscience recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Angiocrine Bioscience
Compare insights from companies similar to Angiocrine Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Angiocrine Bioscience is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Angiocrine Bioscience is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Angiocrine Bioscience.
Angiocrine Bioscience financials insights
Gather financial insights about Angiocrine Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2025
Private Equity
$2.1M
Angiocrine Bioscience Tech Stack
A closer look at the technologies used by Angiocrine Bioscience
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
New Hire
Executive Move
Jeannette Filippone has joined the organization as General Counsel.
Executive Moves, New Hire
Left Company
Executive Move
Funding
Angiocrine Bioscience News & Media
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
Positively impact patients' lives through the reparative powers of E-CEL® Therapies SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved...Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)
SAN DIEGO, Dec. 9, 2022 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that it has been selected by the American Society of Hematology (ASH) for a poster presentation on its Phase 3 registration study AB-205-301 (E-CELERATE), a...Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing
SAN DIEGO, March 29, 2022 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled...Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
SAN DIEGO, March 12, 2021 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Angiocrine Bioscience
Sign Up For FreeTo access detailed company insights
Angiocrine Bioscience specializes in cellular therapies aimed at restoring, regenerating, and repairing tissues and organs. Their innovative E-CEL Therapies are designed to positively impact patients' lives through their reparative capabilities. The company is focused on transforming medicine by leveraging the power of cellular therapies. Their int... Read More
